Gyre Therapeutics (GYRE) Total Non-Current Liabilities: 2014-2024
Historic Total Non-Current Liabilities for Gyre Therapeutics (GYRE) over the last 5 years, with Dec 2024 value amounting to $16.4 million.
- Gyre Therapeutics' Total Non-Current Liabilities rose 17.13% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year increase of 17.13%. This contributed to the annual value of $16.4 million for FY2024, which is 20.15% down from last year.
- Latest data reveals that Gyre Therapeutics reported Total Non-Current Liabilities of $16.4 million as of FY2024, which was down 20.15% from $20.5 million recorded in FY2023.
- Over the past 5 years, Gyre Therapeutics' Total Non-Current Liabilities peaked at $20.5 million during FY2023, and registered a low of $12.5 million during FY2022.
- Over the past 3 years, Gyre Therapeutics' median Total Non-Current Liabilities value was $16.4 million (recorded in 2024), while the average stood at $16.5 million.
- Per our database at Business Quant, Gyre Therapeutics' Total Non-Current Liabilities spiked by 64.31% in 2023 and then decreased by 20.15% in 2024.
- Gyre Therapeutics' Total Non-Current Liabilities (Yearly) stood at $12.5 million in 2022, then skyrocketed by 64.31% to $20.5 million in 2023, then fell by 20.15% to $16.4 million in 2024.